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In Response:
We thank Dr. Toffalorio and co-
workers for their comments and interest in
our article. All their questions were valu-
able, and they reminded us of the potential
problems of our study. As Dr. Toffalorio
commented, standardization and optimi-
zation are big issues in immunohisto-
chemistry (IHC). This is one of the major
obstacles preventing generalization of
IHC data. To maintain the quality of tests
and standardization, we performed several
pilot tests with different antibody con-
centrations in normal lung tissue and
other cancer tissues. After this, we
chose the optimal concentration level,
and this was used in this study. To
minimize the technical error, we made
a tissue array and most of the proce-
dures were performed by an automated
method and not by the manual method.
We initially tried to include a needle
aspiration biopsy specimen, yet it was
difficult to mount the small amount of
tissue on the tissue array, so IHC was
performed by the manual method;
however, the quality of IHC staining
was unstable. So, we discarded the
data drawn from the manual method. It
is our opinion that the method used in
this study was quite reliable and repro-
ducible.
Dr. Toffalorio and coworkers
also questioned about clone 8F1 antibody.
However, another research group in our in-
stitute and other researchers have already
reported studies that were performed us-
ing the same antibody clone.1–3 We think
that this antibody is one of the reliable
antibodies that can be used for IHC of
ERCC1.
In terms of the correction of mul-
tiple variables, we did not perform mul-
tivariate analysis. Because we did not
have a large number of cases in each
stage, we thought it would be impracti-
cal to conduct multivariate analysis on
such a small number of cases. Further-
more, the most important point that
should be addressed was not the differ-
ence in survival but the difference of
protein expression between the primary
tumors and the metastatic lymph nodes,
so we thought that multiple comparison
correction was not a critical prerequisite
for this study. However, we have a plan
to include the results of multivariate
analysis in a future study with a larger
number of cases.
We had 30 N1 and 52 N2 patients
in the study population. Because we se-
lected non-small cell lung cancer pa-
tients with nodal metastasis, those pa-
tients are homogenous in terms of nodal
metastasis in our opinion. We thought
that the T stage was not an important
factor because the purpose of this study
was comparing between the primary tu-
mor and the metastatic nodes, and the
survival in this group of patients is usu-
ally determined by nodal metastasis rather
than the status of the primary tumor. For
the same reason, the treatment method
(such as the extent of surgical resection)
would not be an important factor for the
difference in the protein expression lev-
els. We thought that the treatment in this
study was relatively homogenous in that
all the patients received complete surgi-
cal resection and platinum-based che-
motherapy.
Thanks again for your consider-
ation.
Chang-Hyun Kang, MD
Department of Thoracic and Cardiovascular
Surgery
Seoul National University Hospital
Seoul National University College of
Medicine
Seoul, South Korea
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Serum Concentrations
of Erlotinib at a Dose
of 25 mg Daily
To the Editor:
In this journal, our group recently
reported a retrospective review of the
clinical efficacy of erlotinib at a dose of
25 mg/d for patients with metastatic
non-small cell lung cancers (NSCLCs)
with somatic mutations in the epidermal
growth factor receptor (EGFR) gene.1
The seven patients included in that study
attained a response rate of 71.5% and a
median progression-free survival of 17
months (95% CI, 6–35 months). We
speculated that the serum concentrations
achieved with erlotinib 25 mg/d were
similar to the serum concentrations ob-
served with gefitinib 250 mg/d. Based
on the published phase I trials for these
EGFR tyrosine kinase inhibitors, the
mean serum trough concentration at-
tained with gefitinib 250 mg/d was be-
tween 0.16 and 0.24 g/mL or 0.35 and
0.53 M,2 whereas the mean serum con-
centration measured with erlotinib 25
mg/d was approximately 0.22 g/mL or
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0.51 M.3 However, at the time of our
initial publication, we had not measured
the concentrations of erlotinib in any of
our studied patients.
We now report serum concentra-
tion measured with erlotinib for two of
the seven patients,1 initially described in
our case series of a dose of erlotinib 25
mg/d and for an additional patient4
treated with erlotinib 150 mg/d (Table 1).
All patients had stage IV NSCLCs and
received erlotinib orally. Erlotinib (mo-
lecular weight of 429.90) was measured
using high-performance liquid chroma-
tography with ultraviolet detection.5 The
measured serum concentration of erlo-
tinib, by high-performance liquid chro-
matography, in both patients receiving
25 mg/d exceeded 0.4 M (Table 1),
whereas the concentration measured for
the patient receiving 150 mg/d exceeded
4 M. Skin and gastrointestinal toxici-
ties correlated with the serum concen-
tration of erlotinib.
These updated results further
strengthen our clinical results and pro-
vide additional evidence that a dose of
erlotinib 25 mg/d can lead to serum
concentrations that are similar to those
previously reported with gefitinib 250
mg/d. At doses as low as 0.1 M of
either gefitinib or erlotinib, NSCLC
cell lines with sensitizing EGFR mu-
tation are inhibited and undergo apo-
ptosis.6 Therefore, it is tempting to
speculate that effective doses of ge-
fitinib/erlotinib in NSCLC patients
with sensitizing EGFR mutations are
far below their maximum tolerated
doses in humans. Prospective clinical
trials of erlotinib at lower than ap-
proved doses are warranted and will
help define less-toxic treatment strate-
gies for NSCLC patients whose tu-
mors harbor EGFR mutations.
Daniel B. Costa, MD, PhD
Susumu Kobayashi, MD, PhD
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